Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of TAS-121 in advanced non-small cell lung cancer
jRCT2080222600Phase 1
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-121 in non-small cell lung cancer (NSCLC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS-121, Pharmacokinetics of TAS-121 and 1 more.
02
Drugs
TAS-121
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222600.